Fengcai Zhu to Aged
This is a "connection" page, showing publications Fengcai Zhu has written about Aged.
Connection Strength
0.097
-
Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nat Med. 2021 06; 27(6):1062-1070.
Score: 0.017
-
COVID-19 outbreak following a single patient exposure at an entertainment site: An epidemiological study. Transbound Emerg Dis. 2021 Mar; 68(2):773-781.
Score: 0.016
-
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 08 15; 396(10249):479-488.
Score: 0.016
-
Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance and seroconversion in hepatitis B e antigen-negative chronic infection patients: A population-based prospective cohort. J Viral Hepat. 2018 12; 25(12):1588-1598.
Score: 0.014
-
Preliminary fast diagnosis of severe fever with thrombocytopenia syndrome with clinical and epidemiological parameters. PLoS One. 2017; 12(7):e0180256.
Score: 0.013
-
A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med. 2009 Dec 17; 361(25):2414-23.
Score: 0.008
-
Co-infection with respiratory pathogens among COVID-2019 cases. Virus Res. 2020 08; 285:198005.
Score: 0.004
-
Association of viral load with serum biomakers among COVID-19 cases. Virology. 2020 07; 546:122-126.
Score: 0.004
-
Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China. Expert Rev Vaccines. 2017 11; 16(11):1155-1169.
Score: 0.003
-
A phase 1 randomized open-label clinical study to evaluate the safety and tolerability of a novel recombinant hepatitis E vaccine. Vaccine. 2017 09 05; 35(37):5073-5080.
Score: 0.003